Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 4/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | PTPN7 | P35236 | 2/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21957007 | 0.74 | EPAS1 (0.41) | HTR2AHTR2CARALDH1A1HPGD | |
| SCHEMBL22035528 | 0.74 | NPC1 (0.35) | HTR2A | |
| SCHEMBL30901285 | 0.74 | EPAS1 (0.41) | HTR2AHTR2CARALDH1A1HPGD | |
| SCHEMBL13347574 | 0.73 | HTR2A (0.45) | HTR2AHTR2CARIDO1NR3C2 | |
| SCHEMBL22017132 | 0.71 | HTR2A (0.39) | HTR2AHTR2CIDO1NR3C2PGR | |
| SCHEMBL22035259 | 0.71 | HTR2A (0.39) | HTR2AHTR2CARALDH1A1HPGD | |
| SCHEMBL13347573 | 0.69 | NR3C2 (0.49) | IDO1NR3C2PGR | |
| SCHEMBL20756625 | 0.67 | HTR2A (0.62) | HTR2AHTR2CARALDH1A1HPGD | |
| SCHEMBL16562814 | 0.66 | AR (0.43) | HTR2AHTR2CARALDH1A1HPGD | |
| SCHEMBL15836402 | 0.64 | CYP3A4 (0.41) | HTR2AALDH1A1HPGDNR3C2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174256-B2 | Imidazopyridine derivatives | GILEAD SCIENCES, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | GILEAD SCIENCES, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174256-B2 | Imidazopyridine derivatives | TPMT, IRAK4, CFTR | HTR2A 3478/4885HTR2C 3175/4885AR 2483/4885 |
| US-20200165248-A1 | IMIDAZOPYRIDINE DERIVATIVES | TPMT, IRAK4, CFTR | HTR2A 3478/4885HTR2C 3175/4885AR 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.